Stoke Therapeutics’ (STOK) “Buy” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK) in a research report report published on Wednesday morning,Benzinga reports. Needham & Company LLC currently has a $22.00 target price on the stock.

A number of other equities analysts have also commented on the stock. HC Wainwright restated a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday. Leerink Partners initiated coverage on Stoke Therapeutics in a research note on Monday, October 14th. They set an “outperform” rating and a $18.00 price objective for the company. Wedbush reaffirmed an “outperform” rating and issued a $17.00 price target on shares of Stoke Therapeutics in a report on Thursday, July 11th. Finally, Leerink Partnrs raised Stoke Therapeutics to a “strong-buy” rating in a report on Friday, October 11th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $20.83.

Stoke Therapeutics Trading Up 4.6 %

Shares of STOK stock opened at $13.88 on Wednesday. The firm’s 50 day moving average is $13.21 and its 200 day moving average is $13.72. The stock has a market capitalization of $735.22 million, a P/E ratio of -6.61 and a beta of 0.95. Stoke Therapeutics has a 12 month low of $3.77 and a 12 month high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.05. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The firm had revenue of $4.89 million during the quarter, compared to analyst estimates of $3.46 million. On average, equities analysts predict that Stoke Therapeutics will post -2.1 EPS for the current year.

Insider Buying and Selling at Stoke Therapeutics

In other news, major shareholder Skorpios Trust sold 1,937,500 shares of the firm’s stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $14.05, for a total transaction of $27,221,875.00. Following the transaction, the insider now directly owns 8,906,181 shares of the company’s stock, valued at approximately $125,131,843.05. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 11.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Stoke Therapeutics in the first quarter valued at about $1,224,000. BNP Paribas Financial Markets increased its holdings in Stoke Therapeutics by 86.2% during the 1st quarter. BNP Paribas Financial Markets now owns 14,330 shares of the company’s stock valued at $193,000 after purchasing an additional 6,636 shares during the period. State Board of Administration of Florida Retirement System bought a new position in Stoke Therapeutics during the 1st quarter valued at approximately $141,000. Vanguard Group Inc. lifted its holdings in Stoke Therapeutics by 4.1% in the 1st quarter. Vanguard Group Inc. now owns 1,715,554 shares of the company’s stock worth $23,160,000 after buying an additional 67,052 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund grew its position in shares of Stoke Therapeutics by 10.2% in the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 263,700 shares of the company’s stock worth $3,560,000 after buying an additional 24,400 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.